HomeCompareBRCN vs MRK

BRCN vs MRK: Dividend Comparison 2026

BRCN yields 454.55% · MRK yields 2.76%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 BRCN wins by $29618.99M in total portfolio value
10 years
BRCN
BRCN
● Live price
454.55%
Share price
$0.44
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$29619.04M
Annual income
$20,672,526,630.46
Full BRCN calculator →
MRK
Merck & Co. Inc.
● Live price
2.76%
Share price
$120.31
Annual div
$3.32
5Y div CAGR
32.7%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$56.8K
Annual income
$9,798.13
Full MRK calculator →

Portfolio growth — BRCN vs MRK

📍 BRCN pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodBRCNMRK
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, BRCN + MRK cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
BRCN pays
MRK pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

BRCN
Annual income on $10K today (after 15% tax)
$38,636.36/yr
After 10yr DRIP, annual income (after tax)
$17,571,647,635.89/yr
MRK
Annual income on $10K today (after 15% tax)
$234.56/yr
After 10yr DRIP, annual income (after tax)
$8,328.41/yr
At 15% tax rate, BRCN beats the other by $17,571,639,307.48/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of BRCN + MRK for your $10,000?

BRCN: 50%MRK: 50%
100% MRK50/50100% BRCN
Portfolio after 10yr
$14809.55M
Annual income
$10,336,268,214.30/yr
Blended yield
69.79%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MRK right now

BRCN
No analyst data
MRK
Analyst Ratings
25
Buy
11
Hold
1
Sell
Consensus: Buy
Price Target
$128.54
+6.8% upside vs current
Range: $100.00 — $150.00
Altman Z
4.0
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

BRCN buys
0
MRK buys
0
No recent congressional trades found for BRCN or MRK in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricBRCNMRK
Forward yield454.55%2.76%
Annual dividend / share$2.00$3.32
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%32.7%
Portfolio after 10y$29619.04M$56.8K
Annual income after 10y$20,672,526,630.46$9,798.13
Total dividends collected$28823.07M$28.9K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: BRCN vs MRK ($10,000, DRIP)

YearBRCN PortfolioBRCN Income/yrMRK PortfolioMRK Income/yrGap
1← crossover$56,155$45,454.55$11,206$366.19+$44.9KBRCN
2$298,635$238,549.47$12,650$502.35+$286.0KBRCN
3$1,505,172$1,185,632.86$14,407$694.19+$1.49MBRCN
4$7,195,392$5,584,858.27$16,585$967.82+$7.18MBRCN
5$32,650,572$24,951,502.07$19,342$1,363.89+$32.63MBRCN
6$140,751,597$105,815,484.50$22,913$1,947.19+$140.73MBRCN
7$576,916,626$426,312,417.48$27,662$2,823.89+$576.89MBRCN
8$2,250,367,516$1,633,066,726.35$34,159$4,173.35+$2250.33MBRCN
9$8,361,231,346$5,953,338,104.06$43,337$6,308.80+$8361.19MBRCN
10$29,619,044,171$20,672,526,630.46$56,776$9,798.13+$29618.99MBRCN

BRCN vs MRK: Complete Analysis 2026

BRCNStock

Burcon NutraScience Corporation, together with its subsidiaries, develops plant proteins and ingredients for use in the food and beverage industries in Canada. The company's products include Peazazz, a pea protein for use in dairy alternatives, ready-to-drink beverages, dry blended beverages, bars, baked goods, and meat substitute products; and Peazac and Peazac 850, a pea protein for plant-based meat alternative products, ready-to-mix powders, ready-to-mix beverages, dairy alternatives, and nutrition bars, as well as other applications requiring the most neutral flavor and moderate viscosity. It provides Puratein, a canola protein isolate for use in meat alternatives, such as burgers, sausages, and nutrition bars; Supertein, a canola protein that is a light-colored powder for use in non-dairy frozen desserts, egg alternative, plant-based marshmallows and ready-to-mix beverages, whipped toppings, and plant-based bars; and Nutratein, a canola protein comprising a mixture of globulin and albumin proteins for use in meat and egg alternatives, and other plant-based functional foods. In addition, the company offers Nutratein-PS and Nutratein-TZ, a blend of Peazac pea protein; and CLARISOY, a soy protein for use in sports nutrition beverages, citrus-based drinks, fruit-flavored beverages, lemonades, powdered beverage mixes, and other foods and nutritional products. Further, it provides MeritPro, a nutritional protein blend, including allergen-free, gluten-free, non-dairy, non-GMO, and vegan. The company was formerly known as Burcon Capital Corp. and changed its name to Burcon NutraScience Corporation in October 1999. The company was incorporated in 1998 and is headquartered in Vancouver, Canada.

Full BRCN Calculator →

MRKHealthcare

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Full MRK Calculator →
📬

Get this BRCN vs MRK comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

BRCN vs SCHDBRCN vs JEPIBRCN vs OBRCN vs KOBRCN vs MAINBRCN vs JNJBRCN vs ABBVBRCN vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.